316 results on '"Simonneau G"'
Search Results
2. Traitement chirurgical de l’hypertension pulmonaire thromboembolique
3. Physiopathologie de l’hypertension pulmonaire thromboembolique chronique et traitement des formes non chirurgicales (inopérables)
4. Medical bridging therapy before pulmonary endarterectomy?
5. External Validation of a Refined 4 Strata Risk Assessment Score from the French Pulmonary Hypertension Registry
6. ERS statement on chronic thromboembolic pulmonary hypertension
7. Changes in cMRI parameters following a switch to riociguat from phosphodiesterase type 5 inhibitors (PDE5i) in patients with pulmonary arterial hypertension: a REPLACE substudy
8. Treatment effect of selexipag on time to disease progression when initiated early in pulmonary arterial hypertension (PAH) patients: GRIPHON and TRITON pooled analysis
9. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
10. Switching to Riociguat from Phosphodiesterase-5 Inhibitors, With or Without Endothelin Receptor Antagonists, in Patients with Pulmonary Arterial Hypertension: Results from the REPLACE Study
11. BPA and Riociguat for the Management of Inoperable CTEPH: Results of the Extension Study Following the RACE Randomized Controlled Trial (RCT)
12. Screening for Pulmonary Arterial Hypertension in Adults Carrying a BMPR2 Mutation
13. Initial Triple Oral Therapy in Pulmonary Arterial Hypertension (PAH): Extended Long-Term Outcome Data from TRITON
14. Analysis of Risk Assessment Tools in the REPLACE Study
15. S94 Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON
16. Trithérapie initiale dans l’hypertension artérielle pulmonaire
17. Pulmonary hypertension in orphan lung diseases
18. Long-term outcomes in newly diagnosed pulmonary arterial hypertension (PAH) patients receiving initial triple oral combination therapy: insights from the randomised controlled TRITON study
19. Efficacy and Safety of Initial Triple Oral Versus Initial Double Oral Combination Therapy in Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH): Results of the Randomized Controlled TRITON Study
20. Safety of Riociguat for the Treatment of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease: Data from the EXPERT Registry
21. Safety of Riociguat in Patients Receiving Concomitant Prostanoids: Data from the EXPERT Registry
22. Safety of Riociguat in Patients with Inoperable CTEPH and Persistent/Recurrent CTEPH: Data from the EXPERT Registry
23. Safety of Riociguat in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension with Concomitant Novel Oral Anticoagulants or Vitamin K Antagonist Use: Data from the EXPERT Registry
24. Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities
25. The impact of time from diagnosis at baseline on long-term outcome in the GRIPHON Study: Selexipag in pulmonary arterial hypertension (PAH)
26. Hypertension pulmonaire associée à la neurofibromatose de type 1 : données du registre français de l’hypertension pulmonaire
27. World Health Organization classification and risk factors for pulmonary arterial hypertension
28. Klippel-Trenaunay syndrome as a rare cause of chronic thromboemboembolic pulmonary hypertension
29. THE IMPACT OF TIME FROM DIAGNOSIS AT BASELINE ON LONG-TERM OUTCOME IN THE GRIPHON STUDY: SELEXIPAG IN PULMONARY ARTERIAL HYPERTENSION (PAH)
30. P2540Sex-specific differences in the clinical presentation, surgical complications, and course of chronic thromboembolic pulmonary hypertension
31. 4973Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities
32. Chronic thromboembolic and pulmonary arterial hypertension share right ventricular and pulmonary artery CMR features
33. Assessment of the REPLACE Study Composite Endpoint in the PATENT Study and Association with Long-Term Outcomes in Riociguat-Treated Patients
34. The Impact of Time from Diagnosis at Baseline on Long-Term Outcome in the GRIPHON Study: Selexipag in Pulmonary Arterial Hypertension
35. Safety of Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension: Final Data Cut from the EXPERT Registry
36. Safety of Riociguat for the Treatment of Pulmonary Arterial Hypertension: Final Data Cut from the EXPERT Registry
37. Impact of Initial Triple Combination Therapy on Long-Term Survival in Pulmonary Arterial Hypertension (PAH)
38. Long-Term Safety, Tolerability and Efficacy of Macitentan in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension: The MERIT-1 Study and Its Open-Label Extension MERIT-2
39. Preoperative C-Reactive Protein Predicts Early Postoperative Outcomes after Pulmonary Endarterectomy in Patients with Chronic Thromboembolic Pulmonary Hypertension
40. Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study
41. S122 Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension
42. P2614Factors associated with survival in patients with not-operated chronic thromboembolic pulmonary hypertension (CTEPH) in the modern management era
43. Switching from PDE5i to Riociguat in the RESPITE Study: Effect on Right Heart Function
44. Outcome of Heart-Lung or Double-Lung Transplantation in Pulmonary Hypertension Secondary to Congenital Heart Diseases
45. Efficacy and safety of macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): Results from the randomized controlled MERIT study
46. Using controlled and real-world data in concert to assess survival in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL
47. Pulmonary arterial hypertension-related morbidity is prognostic for survival: Insights from the SERAPHIN and GRIPHON studies
48. La maladie veino-occlusive pulmonaire
49. Évaluation des échanges érythrocytaires dans la prise en charge de l’hypertension pulmonaire précapillaire chronique associée à la drépanocytose
50. Hypertension pulmonaire sévère associée aux maladies pulmonaires chroniques post-tabagiques bronchiques ou emphysémateuses
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.